Dummy Global Artificial Intelligence (AI) in Drug Discovery Market, By Component (Software, Service), Technology (Machine learning {Deep Learning}), Application Type (Target Identification), Therapeutic Area (Oncology), End-use (CRO), By Region and forecast till 2030

Report ID : AMR1003529 | Industries : Healthcare | Published On :November 2023 | Page Count : 180

Global Artificial Intelligence (AI) in Drug Discovery Market, By Component (Software, Service), Technology (Machine learning {Deep Learning}), Application Type (Target Identification), Therapeutic Area (Oncology), End-use (CRO), By Region and forecast till 2030.

Global Artificial Intelligence (AI) in Drug Discovery Market

Global Artificial Intelligence (AI) in Drug Discovery Market was valued at USD 885.32 million in 2022 and is slated to reach USD 1,39,88.71 million by 2030 at a CAGR of 23.87% from 2023-2030.

The use of technology powered by artificial intelligence (AI) to automate and hasten the drug development process is known as artificial intelligence (AI) in drug discovery. This covers duties including finding novel drug targets, creating new medications, figuring out how to make them more effectively, and maximising drug production. Artificial intelligence (AI) has the ability to analyse vast volumes of data, spot patterns, and make predictions that would be challenging or impossible for people to make on their own. Researchers may find novel medications more rapidly and effectively as a result of this.

Market Drivers

The demand for novel and efficient therapies is growing as more individuals are affected by chronic diseases. AI can be used to find novel therapeutic targets, create novel drug compounds, and forecast the toxicity and efficacy of possible treatments that would address market expansion. An estimated $1 billion or more goes into the development of a new medicine.

AI can assist in lowering the cost of drug development by automating processes like data analysis and compound screening. As a result of cutting down on the time needed for the drug discovery process, demand for artificial intelligence in drug discovery is increasing. This has led to the adoption of AI-powered technologies, which can assist in the discovery and development of novel drugs in days or months as opposed to the conventional method, which requires years.

The market for AI in drug discovery is anticipated to grow further as a result of rising healthcare spending and improvements in the healthcare system. AI has the potential to revolutionise drug discovery by drastically speeding up the R&D process, lowering the cost and duration of drug development, and increasing the likelihood that a medicine will be approved. Additionally, AI can improve the efficiency of drug repurposing studies.

The market is driven by an increase in cross-industry alliances and partnerships. A rise in financing for R&D activities, including AI technology in the field of drug research, and an increase in the significance of AI in drug discovery and development are expected to drive the growth of the global market. As a result, the market is being driven by an increase in cross-industry alliances and collaborations.

Market Restraints

The pharmaceutical industry is data-driven, and in order to train and produce reliable predictions, AI algorithms require a lot of data. The market expansion will be constrained by the dearth of high-quality data available for AI in drug discovery, particularly for uncommon diseases and neglected diseases. The legal framework for using AI in drug discovery is continually developing. Because there are questions regarding the efficacy and safety of AI-powered pharmaceuticals and because there are no clear regulatory requirements, the market is constrained.

The development and implementation of AI technologies can be costly. For poor nations and smaller businesses, this may be a hindrance.

Additionally, there is a lack of AI expertise in the pharmaceutical sector. Due to this, it may be challenging to locate and hire the talent required to create and implement AI-powered drug development solutions that impede market expansion.

Covid-19 Impact

The COVID-19 pandemic has had a conflicting effect on the market for AI in drug research. On the one hand, the pandemic has heightened the need for innovative, potent COVID-19 medications. As a result, systems for AI-based drug development have seen increased investment. On the other hand, the epidemic has also hampered the world's supply chain, making it challenging for some businesses to have access to the AI technologies they require. The implementation of artificial intelligence (AI) in drug discovery has been expedited by the COVID-19 pandemic. For instance, AI has been used to design new therapeutic compounds, find new pharmacological targets for COVID-19, and forecast the effectiveness and toxicity of potential treatment options.

Recent Development

To create and implement real-time AI applications, NVIDIA Corporation introduced Clara Holoscan MGX in March 2022. Clara Holoscan MGX enhances the Clara Holoscan platform by offering a comprehensive, medical-grade reference architecture as well as ongoing software support, accelerating innovation in the medical device sector. This will assist the business in achieving superior AI performance in the medical field for procedures, diagnostics, and drug development.

Restylane Lyft, a hyaluronic acid dermal filler for the treatment of moderate to severe face creases and folds, was given FDA approval by Galderma in February 2023.

AstraZeneca has chosen an additional novel target for Idiopathic Pulmonary Fibrosis (IPF) for its drug development portfolio, according to a milestone announcement made by Benevolent AI, a top clinical-stage AI-enabled drug discovery business, in May 2022. Benevolent AI will get a payment from AstraZeneca as a result. In two disease domains, IPF and chronic renal disease, the Benevolent Platform was used to identify this third novel target from the cooperation. AstraZeneca then verified the target and chose it for portfolio entry. The agreement with AstraZeneca was recently expanded to cover two additional disease areas, including systemic lupus erythematosus and heart failure, and was inked in January 2022. This has aided the business in fortifying its teamwork.

Market Segmentation

Global Artificial Intelligence (AI) in Drug Discovery Market is segmented into By Component, Technology, Application Type, Therapeutic Area, and End Use.

By Component such as Software Services. By Technology such as Machine Learning Deep Learning Supervised Learning Unsupervised Learning Other Machine Learning Technologies Other Technologies.

By Application Type such as Molecular library screening Target Identification Drug Optimization and Repurposing De novo Drug Designing Preclinical Testing. By Therapeutic Area such as Oncology Neurodegenerative Diseases Inflammatory Infectious Diseases Metabolic Diseases Rare Diseases Cardiovascular Diseases Other Therapeutic Areas. By End Use such as Pharmaceutical and Biotechnology Companies Contract Research Organization (CROs).

Regional Analysis

The market is dominated by North America. The market growth is anticipated to be boosted by the rising R&D spending and adoption of AI technology in the North American area over the past several years. Due to the significant presence of AI technology suppliers like IBM, Google, Microsoft, and others, the U.S. leads the region of North America.

Key Players

This report includes a list of numerous Key Players, NVIDIA Corporation, IBM Corp., Atomwise Inc., Microsoft, Benevolent AI, Aria Pharmaceuticals, Inc., DEEP GENOMICS, Exscientia, Cloud, Insilico Medicine, Cyclica, NuMedii, Inc., Envisagenics, Owkin Inc., BERG LLC, Schrödinger, Inc., XtalPi Inc. and BIOAGE Inc.

Market Taxonomy

By Component

Software
Services

By Technology

Machine Learning
Deep Learning
Supervised Learning
Unsupervised Learning
Other Machine Learning Technologies
Other Technologies

By Application Type

Molecular library screening
Target Identification
Drug Optimization and Repurposing
De novo Drug Designing
Preclinical Testing

By Therapeutic Area

Oncology
Neurodegenerative Diseases
Inflammatory
Infectious Diseases
Metabolic Diseases
Rare Diseases
Cardiovascular Diseases
Other Therapeutic Areas

By End-use

Pharmaceutical and Biotechnology Companies
Contract Research Organization (CROs).

By Region

North America

U.S.
Canada
Mexico

Latin America

Brazil
Argentina
Colombia
Peru
Chile
Venezuela
Rest of Latin America

Europe

Germany
France
UK
Russia
Italy
Spain
Rest of Europe

Asia Pacific

China
Japan
India
South Korea
Australia
New Zealand
Singapore
Malaysia
Rest of Asia Pacific

Middle East & Africa

Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest Middle East & Africa

Global Artificial Intelligence (AI) in Drug Discovery Market

1 Introduction

1.1 Objective of the Study

1.2 Market Definition

1.3 Market Scope

2 Research Methodology

2.1 Data Mining

2.2 Validation

2.3 Primary Interviews

2.4 List of Data Sources

3 Executive Summary

4 Global Artificial Intelligence (AI) in Drug Discovery Market Outlook

4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities

4.2.4 Cumulative Impact due to Recent Energy Crisis

4.2.5 Cumulative Impact due to Nearing Economic Downturn

4.2.6 Post Covid-19 World Supply & Demand Conditions

4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 Global Artificial Intelligence (AI) in Drug Discovery Market, By Component

5.1 Y-o-Y Growth Comparison, By Component

5.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Component

5.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component

5.3.1 Software

5.3.2 Services

6 Global Artificial Intelligence (AI) in Drug Discovery Market, By Technology

6.1 Y-o-Y Growth Comparison, By Technology

6.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Technology

6.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology

6.3.1 Machine Learning

6.3.2 Deep Learning

6.3.3 Supervised Learning

6.3.4 Unsupervised Learning

6.3.5 Other Machine Learning Technologies

6.3.6 Other Technologies

7 Global Artificial Intelligence (AI) in Drug Discovery Market, By Application Type

7.1 Y-o-Y Growth Comparison, By Application Type

7.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Application Type

7.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type

7.3.1 Molecular library screening

7.3.2 Target Identification

7.3.3 Drug Optimization and Repurposing

7.3.4 De novo Drug Designing

7.3.5 Preclinical Testing

8 Global Artificial Intelligence (AI) in Drug Discovery Market, By Therapeutic Area

8.1 Y-o-Y Growth Comparison, By Therapeutic Area

8.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Therapeutic Area

8.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area

8.3.1 Oncology

8.3.2 neurodegenerative diseases

8.3.3 Inflammatory

8.3.4 Infectious Diseases

8.3.5 Metabolic Diseases

8.3.6 Rare Diseases

8.3.7 cardiovascular diseases

8.3.8 Other Therapeutic Areas

9 Global Artificial Intelligence (AI) in Drug Discovery Market, By End User

9.1 Y-o-Y Growth Comparison, By End User

9.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By End User

9.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User

9.3.1 Pharmaceutical and Biotechnology Companies

9.3.2 Contract Research Organization (CROs).

10 Global Artificial Intelligence (AI) in Drug Discovery Market, By Region

10.1 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Region

10.2 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Region

10.3 Global Artificial Intelligence (AI) in Drug Discovery Market Trends and Forecast, By Region

11 North America Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)

11.1 Introduction

11.2 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component

11.3 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology

11.4 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type

11.5 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area

11.6 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User

11.7 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country

11.7.1 U.S.

11.7.1.1 Market Size and Forecast, By Component

11.7.1.2 Market Size and Forecast, By Technology

11.7.1.3 Market Size and Forecast, By Application Type

11.7.1.4 Market Size and Forecast, By Therapeutic Area

11.7.1.5 Market Size and Forecast, By End User

11.7.2 Canada

11.7.2.1 Market Size and Forecast, By Component

11.7.2.2 Market Size and Forecast, By Technology

11.7.2.3 Market Size and Forecast, By Application Type

11.7.2.4 Market Size and Forecast, By Therapeutic Area

11.7.2.5 Market Size and Forecast, By End User

11.7.3 Mexico

11.7.3.1 Market Size and Forecast, By Component

11.7.3.2 Market Size and Forecast, By Technology

11.7.3.3 Market Size and Forecast, By Application Type

11.7.3.4 Market Size and Forecast, By Therapeutic Area

11.7.3.5 Market Size and Forecast, By End User

12 Europe Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)

12.1 Introduction

12.2 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component

12.3 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology

12.4 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type

12.5 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area

12.6 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User

12.7 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country

12.7.1.1 Market Size and Forecast, By Component

12.7.1.2 Market Size and Forecast, By Technology

12.7.1.3 Market Size and Forecast, By Application Type

12.7.1.4 Market Size and Forecast, By Therapeutic Area

12.7.1.5 Market Size and Forecast, By End User

12.7.2 France

12.7.2.1 Market Size and Forecast, By Component

12.7.2.2 Market Size and Forecast, By Technology

12.7.2.3 Market Size and Forecast, By Application Type

12.7.2.4 Market Size and Forecast, By Therapeutic Area

12.7.2.5 Market Size and Forecast, By End User

12.7.3 UK

12.7.3.1 Market Size and Forecast, By Component

12.7.3.2 Market Size and Forecast, By Technology

12.7.3.3 Market Size and Forecast, By Application Type

12.7.3.4 Market Size and Forecast, By Therapeutic Area

12.7.3.5 Market Size and Forecast, By End User

12.7.4 Russia

12.7.4.1 Market Size and Forecast, By Component

12.7.4.2 Market Size and Forecast, By Technology

12.7.4.3 Market Size and Forecast, By Application Type

12.7.4.4 Market Size and Forecast, By Therapeutic Area

12.7.4.5 Market Size and Forecast, By End User

12.7.5 Italy

12.7.5.1 Market Size and Forecast, By Component

12.7.5.2 Market Size and Forecast, By Technology

12.7.5.3 Market Size and Forecast, By Application Type

12.7.5.4 Market Size and Forecast, By Therapeutic Area

12.7.5.5 Market Size and Forecast, By End User

12.7.6 Spain

12.7.6.1 Market Size and Forecast, By Component

12.7.6.2 Market Size and Forecast, By Technology

12.7.6.3 Market Size and Forecast, By Application Type

12.7.6.4 Market Size and Forecast, By Therapeutic Area

12.7.6.5 Market Size and Forecast, By End User

12.7.7 Rest of Europe

12.7.7.1 Market Size and Forecast, By Component

12.7.7.2 Market Size and Forecast, By Technology

12.7.7.3 Market Size and Forecast, By Application Type

12.7.7.4 Market Size and Forecast, By Therapeutic Area

12.7.7.5 Market Size and Forecast, By End User

13 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)

13.1 Introduction

13.2 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component

13.3 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology

13.4 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type

13.5 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area

13.6 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User

13.7 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country

13.7.1 China

13.7.1.1 Market Size and Forecast, By Component

13.7.1.2 Market Size and Forecast, By Technology

13.7.1.3 Market Size and Forecast, By Application Type

13.7.1.4 Market Size and Forecast, By Therapeutic Area

13.7.1.5 Market Size and Forecast, By End User

13.7.2 Japan

13.7.2.1 Market Size and Forecast, By Component

13.7.2.2 Market Size and Forecast, By Technology

13.7.2.3 Market Size and Forecast, By Application Type

13.7.2.4 Market Size and Forecast, By Therapeutic Area

13.7.2.5 Market Size and Forecast, By End User

13.7.3 India

13.7.3.1 Market Size and Forecast, By Component

13.7.3.2 Market Size and Forecast, By Technology

13.7.3.3 Market Size and Forecast, By Application Type

13.7.3.4 Market Size and Forecast, By Therapeutic Area

13.7.3.5 Market Size and Forecast, By End User

13.7.4 South Korea

13.7.4.1 Market Size and Forecast, By Component

13.7.4.2 Market Size and Forecast, By Technology

13.7.4.3 Market Size and Forecast, By Application Type

13.7.4.4 Market Size and Forecast, By Therapeutic Area

13.7.4.5 Market Size and Forecast, By End User

13.7.5 Australia

13.7.5.1 Market Size and Forecast, By Component

13.7.5.2 Market Size and Forecast, By Technology

13.7.5.3 Market Size and Forecast, By Application Type

13.7.5.4 Market Size and Forecast, By Therapeutic Area

13.7.5.5 Market Size and Forecast, By End User

13.7.6 New Zealand

13.7.6.1 Market Size and Forecast, By Component

13.7.6.2 Market Size and Forecast, By Technology

13.7.6.3 Market Size and Forecast, By Application Type

13.7.6.4 Market Size and Forecast, By Therapeutic Area

13.7.6.5 Market Size and Forecast, By End User

13.7.7 Singapore

13.7.7.1 Market Size and Forecast, By Component

13.7.7.2 Market Size and Forecast, By Technology

13.7.7.3 Market Size and Forecast, By Application Type

13.7.7.4 Market Size and Forecast, By Therapeutic Area

13.7.7.5 Market Size and Forecast, By End User

13.7.8 Malaysia

13.7.8.1 Market Size and Forecast, By Component

13.7.8.2 Market Size and Forecast, By Technology

13.7.8.3 Market Size and Forecast, By Application Type

13.7.8.4 Market Size and Forecast, By Therapeutic Area

13.7.8.5 Market Size and Forecast, By End User

13.7.9 Rest of Asia

13.7.9.1 Market Size and Forecast, By Component

13.7.9.2 Market Size and Forecast, By Technology

13.7.9.3 Market Size and Forecast, By Application Type

13.7.9.4 Market Size and Forecast, By Therapeutic Area

13.7.9.5 Market Size and Forecast, By End User

14 Latin America Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)

14.1 Introduction

14.2 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component

14.3 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology

14.4 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type

14.5 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area

14.6 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User

14.7 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country

14.7.1 Brazil

14.7.1.1 Market Size and Forecast, By Component

14.7.1.2 Market Size and Forecast, By Technology

14.7.1.3 Market Size and Forecast, By Application Type

14.7.1.4 Market Size and Forecast, By Therapeutic Area

14.7.1.5 Market Size and Forecast, By End User

14.7.2 Argentina

14.7.2.1 Market Size and Forecast, By Component

14.7.2.2 Market Size and Forecast, By Technology

14.7.2.3 Market Size and Forecast, By Application Type

14.7.2.4 Market Size and Forecast, By Therapeutic Area

14.7.2.5 Market Size and Forecast, By End User

14.7.3 Colombia

14.7.3.1 Market Size and Forecast, By Component

14.7.3.2 Market Size and Forecast, By Technology

14.7.3.3 Market Size and Forecast, By Application Type

14.7.3.4 Market Size and Forecast, By Therapeutic Area

14.7.3.5 Market Size and Forecast, By End User

14.7.4 Peru

14.7.4.1 Market Size and Forecast, By Component

14.7.4.2 Market Size and Forecast, By Technology

14.7.4.3 Market Size and Forecast, By Application Type

14.7.4.4 Market Size and Forecast, By Therapeutic Area

14.7.4.5 Market Size and Forecast, By End User

14.7.5 Chile

14.7.5.1 Market Size and Forecast, By Component

14.7.5.2 Market Size and Forecast, By Technology

14.7.5.3 Market Size and Forecast, By Application Type

14.7.5.4 Market Size and Forecast, By Therapeutic Area

14.7.5.5 Market Size and Forecast, By End User

14.7.6 Venezuela

14.7.6.1 Market Size and Forecast, By Component

14.7.6.2 Market Size and Forecast, By Technology

14.7.6.3 Market Size and Forecast, By Application Type

14.7.6.4 Market Size and Forecast, By Therapeutic Area

14.7.6.5 Market Size and Forecast, By End User

14.7.7 Rest of Latin America

14.7.7.1 Market Size and Forecast, By Component

14.7.7.2 Market Size and Forecast, By Technology

14.7.7.3 Market Size and Forecast, By Application Type

14.7.7.4 Market Size and Forecast, By Therapeutic Area

14.7.7.5 Market Size and Forecast, By End User

15 Middle East Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)

15.1 Introduction

15.2 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component

15.3 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology

15.4 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type

15.5 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area

15.6 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User

15.7 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country

15.7.1 Saudi Arabia

15.7.1.1 Market Size and Forecast, By Component

15.7.1.2 Market Size and Forecast, By Technology

15.7.1.3 Market Size and Forecast, By Application Type

15.7.1.4 Market Size and Forecast, By Therapeutic Area

15.7.1.5 Market Size and Forecast, By End User

15.7.2 UAE

15.7.2.1 Market Size and Forecast, By Component

15.7.2.2 Market Size and Forecast, By Technology

15.7.2.3 Market Size and Forecast, By Application Type

15.7.2.4 Market Size and Forecast, By Therapeutic Area

15.7.2.5 Market Size and Forecast, By End User

15.7.3 Egypt

15.7.3.1 Market Size and Forecast, By Component

15.7.3.2 Market Size and Forecast, By Technology

15.7.3.3 Market Size and Forecast, By Application Type

15.7.3.4 Market Size and Forecast, By Therapeutic Area

15.7.3.5 Market Size and Forecast, By End User

15.7.4 Kuwait

15.7.4.1 Market Size and Forecast, By Component

15.7.4.2 Market Size and Forecast, By Technology

15.7.4.3 Market Size and Forecast, By Application Type

15.7.4.4 Market Size and Forecast, By Therapeutic Area

15.7.4.5 Market Size and Forecast, By End User

15.7.5 South Africa

15.7.5.1 Market Size and Forecast, By Component

15.7.5.2 Market Size and Forecast, By Technology

15.7.5.3 Market Size and Forecast, By Application Type

15.7.5.4 Market Size and Forecast, By Therapeutic Area

15.7.5.5 Market Size and Forecast, By End User

15.7.6 Rest of Middle East & Africa

15.7.6.1 Market Size and Forecast, By Component

15.7.6.2 Market Size and Forecast, By Technology

15.7.6.3 Market Size and Forecast, By Application Type

15.7.6.4 Market Size and Forecast, By Therapeutic Area

15.7.6.5 Market Size and Forecast, By End User

16 Competitive Analysis

16.1 Competition Dashboard

16.2 Market share Analysis of Top Vendors

16.3 Key Development Strategies

17 Company Profiles

17.1 IBM Corp

17.1.2 Offerings

17.1.3 Key Financials

17.1.4 Business Segment & Geographic Overview

17.1.5 Key Market Developments

17.1.6 Key Strategies

17.2 NVIDIA Corporation

17.2.1 Overview

17.2.2 Offerings

17.2.3 Key Financials

17.2.4 Business Segment & Geographic Overview

17.2.5 Key Market Developments

17.2.6 Key Strategies

17.3 Atomwise Inc

17.3.1 Overview

17.3.2 Offerings

17.3.3 Key Financials

17.3.4 Business Segment & Geographic Overview

17.3.5 Key Market Developments

17.3.6 Key Strategies

17.4 Microsoft, Benevolent AI

17.4.1 Overview

17.4.2 Offerings

17.4.3 Key Financials

17.4.4 Business Segment & Geographic Overview

17.4.5 Key Market Developments

17.4.6 Key Strategies

17.5 Aria Pharmaceuticals

17.5.1 Overview

17.5.2 Offerings

17.5.3 Key Financials

17.5.4 Business Segment & Geographic Overview

17.5.5 Key Market Developments

17.5.6 Key Strategies

17.6 DEEP GENOMICS

17.6.1 Overview

17.6.2 Offerings

17.6.3 Key Financials

17.6.4 Business Segment & Geographic Overview

17.6.5 Key Market Developments

17.6.6 Key Strategies

17.7 Exscientia

17.7.1 Overview

17.7.2 Offerings

17.7.3 Key Financials

17.7.4 Business Segment & Geographic Overview

17.7.5 Key Market Developments

17.7.6 Key Strategies

17.8 Alphabet (DeepMind)

17.8.1 Overview

17.8.2 Offerings

17.8.3 Key Financials

17.8.4 Business Segment & Geographic Overview

17.8.5 Key Market Developments

17.8.6 Key Strategies

17.9 Insilico Medicine

17.9.1 Overview

17.9.2 Offerings

17.9.3 Key Financials

17.9.4 Business Segment & Geographic Overview

17.9.5 Key Market Developments

17.9.6 Key Strategies

17.10 Cyclica

17.10.1 Overview

17.10.2 Offerings

17.10.3 Key Financials

17.10.4 Business Segment & Geographic Overview

17.10.5 Key Market Developments

17.10.6 Key Strategies